Literature DB >> 2964079

Immunoregulatory lymphokines in rheumatoid joints. II. Production by and responsiveness to interleukin-2 of eluted synovial tissue cells.

J Hovdenes1, T Egeland.   

Abstract

Since the role of interleukin-2 (IL-2) in rheumatoid synovial joints has been debated, we examined IL-2 production by, and IL-2 responsiveness of, cells eluted from synovial tissue (ST) of patients with rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA). IL-2 was not detected in unstimulated cell-culture supernatants from any of the four RA patients tested, but it was present in small amounts in supernatants of unstimulated cultures derived from three of seven JRA patients studied. After PHA stimulation, IL-2 was detected in corresponding supernatants from all RA and JRA patients and from normal mononuclear cells (MNC). There was no significant difference in IL-2 activity between supernatants of normal MNC and supernatants from either RA or JRA patients. The eluted cells showed a proliferative response to recombinant IL-2. Rheumatoid ST cells are thus able to produce and respond to IL-2. Since non-T cells present in the eluates might interfere with IL-2 metabolism, one cannot yet say whether T cells of rheumatoid ST themselves produce and respond to IL-2 in a normal or abnormal way.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2964079     DOI: 10.1007/bf00270526

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Separation of blood leucocytes, granulocytes and lymphocytes.

Authors:  A Boyum
Journal:  Tissue Antigens       Date:  1974

2.  Reduction of excessive background counts in an IL-2 microassay by incubation of indicator cells at 37 degrees C.

Authors:  J P Michalski; C C McCombs
Journal:  J Immunol Methods       Date:  1985-04-08       Impact factor: 2.303

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Elution and characterization of lymphocytes from rheumatoid inflammatory tissue.

Authors:  T G Abrahamsen; S S Froland; J B Natvig; J Pahle
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

5.  Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis.

Authors:  A Fontana; H Hengartner; E Weber; K Fehr; P J Grob; G Cohen
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

6.  Detection and partial characterization of human B cell colony stimulating activity in synovial fluids of patients with rheumatoid arthritis.

Authors:  A C Fay; A Trudgett; J D McCrea; F Kirk; J M Thompson; E S Mitchell; M J Boyd; S D Roberts; T A McNeill
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

7.  Immunoregulatory lymphokines in rheumatoid joints. I. Search for interleukin 2 in synovial fluid.

Authors:  T Egeland; H Lund
Journal:  Scand J Immunol       Date:  1987-01       Impact factor: 3.487

8.  Interleukin 2 production and responsiveness in active and inactive rheumatoid arthritis.

Authors:  R M McKenna; W Ofosu-Appiah; R J Warrington; J A Wilkins
Journal:  J Rheumatol       Date:  1986-02       Impact factor: 4.666

9.  Interleukin 2: the molecule and its function.

Authors:  R J Robb
Journal:  Immunol Today       Date:  1984-07

10.  Inflammatory synovial tissue mononuclear cells release leucocyte migration inhibition factor in antigen- and mitogen-free cultures.

Authors:  T Egeland; O J Mellbye; J A Pahle
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

View more
  2 in total

Review 1.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  P E Lipsky; L S Davis; J J Cush; N Oppenheimer-Marks
Journal:  Springer Semin Immunopathol       Date:  1989

Review 2.  Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.

Authors:  G Vreugdenhil; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.